logo

Press Journals

Methicillin-resistant Staphylococcus aureus (MRSA) Infection Therapeutics Pipeline Supported by Research Funding from Various Agencies

February 2018

MRSA therapeutics currently exhibits a proliferating pipeline with 52 drug candidates, P&S Market Research.

MRSA Therapeutics Pipeline in 2018

MRSA infection caused by specific "staph" bacteria that is often resistant to most of antibiotic treatments. S. aureus (SA) is listed as a ‘superbug’ by U.S. Centers for Disease Control and Prevention (CDC). MRSA can either be present harmlessly on the skin (colonization) or enter the body (e.g. through broken skin) and cause an infection. The study analyzed that MRSA infection therapeutics pipeline comprises approximately 52 drug candidates in different stages of development.

Access Report Summary with TOC on "Methicillin-resistant Staphylococcus aureus (MRSA) Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments" at:https://www.psmarketresearch.com/market-analysis/mrsa-therapeutics-pipeline


Insights on Pipeline Segments

According to the research findings, a majority of the drug candidates for the treatment of MRSA are being developed to be administered by the intravenous route which offers good bioavailability and is considered to be more effective at the target site.

Pipeline Supported by Research Funding from Various Agencies

The players in the MRSA therapeutics pipeline have been receiving increasing support from various organizations in the form of research funding. For instance, Microbiotix Inc received Phase l grants from SBIR for “Inhibitors of wall teichoic acid biosynthesis of Staphylococcus aureus” for a term of two years in February 2012.

MRSA pipeline characterized by Drug candidates with Novel Mechanism of Action

It has been observed that most of the companies are developing drug candidates with novel mechanism of action. Also, the drug candidates have showed positive efficacy in the clinical as well as Pre-Clinical stage of development. For instance, GlaxoSmithKline plc is developing a Phase II drug candidate, GSK 2140944 or Gepotidacin. It is an intravenous, synthetic, Type II topoisomerase inhibitor. If GSK2140944 hits the market, it would be the first topoisomerase inhibitor for gram-negative infections. Savara Pharma's AeroVanc is the first inhaled antibiotic being developed and is in the Phase III stage of clinical trial and has received $5 million fund from Nonprofit Cystic Fibrosis Foundation. If the drug receives the approval, it would be the first inhaled antibiotic to be developed for the treatment of MRSA.

Some of the key players involved in the development of MRSA therapeutics include GlaxoSmithKline plc, Crystal Genomics Inc., and Innovation Pharmaceuticals Inc.

MRSA Therapeutics Pipeline Analysis

  • By Phase
  • By Molecule Type
  • By Route of Administration
  • By Company